Overview

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma

Status:
Active, not recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in tumor glucose utilization, which may allow investigators to obtain an early read out on the impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.

Phase:

Phase 2

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborators:

AstraZeneca
National Cancer Institute (NCI)
Translational Research in Oncology

Treatments:

Deoxyglucose
Fluorodeoxyglucose F18
Osimertinib